Intracerebral hemorrhage outcomes following selective blockade or stimulation of the PGE 2 EP1 receptor

BMC Neuroscience

Sylvain Doré²  Alex Dang¹  Ellis Greene¹  Luke Soshnik-Schierling¹  Nilendra Singh¹  Abdullah S Ahmad¹  Jenna L Leclerc³ 

[1] Department of Anesthesiology, University of Florida, Gainesville, FL, USA;University of Florida College of Medicine, 1275 Center Drive, Gainesville 32610-0159, FL, USA;Department of Neuroscience, University of Florida, Gainesville, FL, USA

关键词: Stroke;    SC-51089;    PECAM;    Neuroprotection;    Neuroinflammation;    Iron;    Gliosis;    EP3;    17-pt-PGE2;   

Others  :  1232541
DOI  :  10.1186/s12868-015-0182-2

 received in 2015-01-13, accepted in 2015-07-13,  发布年份 2015

【 摘 要 】

Background

Inflammation following intracerebral hemorrhage (ICH) significantly contributes to secondary brain damage and poor outcomes. Prostaglandin E ₂(PGE ₂ ) is known to modulate neuroinflammatory responses and is upregulated in response to brain injury as a result of changes in inducible cyclooxygenase 2 (COX-2) and the membrane-bound type of PGE synthase. Inhibition of COX-2 activity has been reported to attenuate ICH-induced brain injury; however, the clinical utility of such drugs is limited due to the potential for severe side effects. Therefore, it is now important to search for downstream targets capable of preferentially modulating PGE ₂signaling, and the four E prostanoid receptors, EP1-4, which are the main targets of PGE ₂ , remain a viable therapeutic option. We have previously shown that EP1 receptor deletion aggravates ICH-induced brain injury and impairs functional recovery, thus the current study aimed to elaborate on these results by including a pharmacologic approach targeting the EP1 receptor.

Results

Chronic post-treatment with the selective EP1 receptor antagonist, SC-51089, increased lesion volume by 30.1 ± 14.5% (p < 0.05) and treatment with the EP1 agonist, 17-pt-PGE ₂ , improved neuromuscular functional recovery on grip strength (p < 0.01) and hanging wire (p < 0.05) behavioral testing. To begin identifying the mechanisms involved in EP1-mediated neuroprotection after ICH, histology was performed to assess ferric iron content, neuroinflammation, leukocyte transendothelial migratory potential, and peripheral neutrophil and immunoglobulin infiltration. Following ICH, mice treated with the antagonist displayed increased ferric iron (p < 0.05) and cortical microgliosis (p < 0.05), whereas treatment with the agonist decreased cortical (p < 0.01) and striatal (p < 0.001) astrogliosis, leukocyte transendothelial migratory potential (p < 0.01), neutrophil infiltration (p < 0.05), and blood brain barrier breakdown (p < 0.05).

Conclusions

In agreement with our previous results, selective antagonism of the EP1 receptor aggravated ICH-induced brain injury. Furthermore, EP1 receptor agonism improved anatomical outcomes and functional recovery. Thus, the present data continues to reinforce a putative role for EP1 as a new and more selective therapeutic target for the treatment of ICH that could reduce the side effects associated with COX-2 inhibition while still exploiting the beneficial effects.

【 授权许可】

   
2015 Leclerc et al.

【 图 表 】

Fig.1.

Fig.2.

Fig.3.

Fig.4.

Fig.1.

Fig.2.

Fig.3.

Fig.4.

【 参考文献 】

• [1]Broderick JP, Adams HP Jr, Barsan W, Feinberg W, Feldmann E, Grotta J, et al.: Guidelines for the management of spontaneous intracerebral hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke J Cereb Circ 1999, 30(4):905-915.
• [2]Qureshi AI, Mendelow AD, Hanley DF: Intracerebral haemorrhage. Lancet 2009, 373(9675):1632-1644.
• [3]Hua Y, Keep RF, Hoff JT, Xi G: Brain injury after intracerebral hemorrhage: the role of thrombin and iron. Stroke J Cereb Circ 2007, 38(2 Suppl):759-762.
• [4]Wang J, Doré S: Inflammation after intracerebral hemorrhage. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab 2007, 27(5):894-908.
• [5]Leclerc JL, Lampert AS, Diller MA, Immergluck JB, Dore S (2015) Prostaglandin E2 EP2 receptor deletion attenuates intracerebral hemorrhage-induced brain injury and improves functional recovery. ASN neuro 7(2). doi:10.1177/1759091415578713
• [6]Fu Y, Hao J, Zhang N, Ren L, Sun N, Li YJ, et al.: Fingolimod for the treatment of intracerebral hemorrhage: a 2-arm proof-of-concept study. JAMA Neurol 2014, 71(9):1092-1101.
• [7]Peeling J, Yan HJ, Corbett D, Xue M, Del Bigio MR: Effect of FK-506 on inflammation and behavioral outcome following intracerebral hemorrhage in rat. Exp Neurol 2001, 167(2):341-347.
• [8]Murakami M, Naraba H, Tanioka T, Semmyo N, Nakatani Y, Kojima F, et al.: Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J Biol Chem 2000, 275(42):32783-32792.
• [9]Glushakov AV, Robbins SW, Bracy CL, Narumiya S, Doré S: Prostaglandin F2alpha FP receptor antagonist improves outcomes after experimental traumatic brain injury. J Neuroinflam 2013, 10:132. BioMed Central Full Text
• [10]Glushakov AV, Fazal JA, Narumiya S, Dore S: Role of the Prostaglandin E2 EP1 Receptor in Traumatic Brain Injury. PLoS One 2014, 9(11):e113689.
• [11]Singh N, Ma B, Leonardo CC, Ahmad AS, Narumiya S, Doré S: Role of PGE(2) EP1 receptor in intracerebral hemorrhage-induced brain injury. Neurotox Res 2013, 24(4):549-559.
• [12]Ahmad AS, Ahmad M, de Brum-Fernandes AJ, Doré S: Prostaglandin EP4 receptor agonist protects against acute neurotoxicity. Brain Res 2005, 1066(1–2):71-77.
• [13]Saleem S, Kim YT, Maruyama T, Narumiya S, Doré S: Reduced acute brain injury in PGE2 EP3 receptor-deficient mice after cerebral ischemia. J Neuroimmunol 2009, 208(1–2):87-93.
• [14]Ahmad AS, Maruyama T, Narumiya S, Dore S: PGE2 EP1 receptor deletion attenuates 6-OHDA-induced Parkinsonism in mice: old switch, new target. Neurotox Res 2013, 23(3):260-266.
• [15]Zhen G, Kim YT, Li RC, Yocum J, Kapoor N, Langer J, et al.: PGE2 EP1 receptor exacerbated neurotoxicity in a mouse model of cerebral ischemia and Alzheimer’s disease. Neurobiol Aging 2012, 33(9):2215-2219.
• [16]Jiang J, Quan Y, Ganesh T, Pouliot WA, Dudek FE, Dingledine R: Inhibition of the prostaglandin receptor EP2 following status epilepticus reduces delayed mortality and brain inflammation. Proc Natl Acad Sci USA 2013, 110(9):3591-3596.
• [17]Chu K, Jeong SW, Jung KH, Han SY, Lee ST, Kim M, et al.: Celecoxib induces functional recovery after intracerebral hemorrhage with reduction of brain edema and perihematomal cell death. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab 2004, 24(8):926-933.
• [18]Sinn DI, Lee ST, Chu K, Jung KH, Song EC, Kim JM, Park DK, Kim M, Roh JK: Combined neuroprotective effects of celecoxib and memantine in experimental intracerebral hemorrhage. Neurosci Lett 2007, 411(3):238-242.
• [19]Rojas A, Jiang J, Ganesh T, Yang MS, Lelutiu N, Gueorguieva P, Dingledine R: Cyclooxygenase-2 in epilepsy. Epilepsia 2014, 55(1):17-25.
• [20]Polascheck N, Bankstahl M, Loscher W: The COX-2 inhibitor parecoxib is neuroprotective but not antiepileptogenic in the pilocarpine model of temporal lobe epilepsy. Exp Neurol 2010, 224(1):219-233.
• [21]Teismann P, Tieu K, Choi DK, Wu DC, Naini A, Hunot S, et al.: Cyclooxygenase-2 is instrumental in Parkinson’s disease neurodegeneration. Proc Natl Acad Sci USA 2003, 100(9):5473-5478.
• [22]Andreasson K: Emerging roles of PGE2 receptors in models of neurological disease. Prostaglandins Other Lipid Mediat 2010, 91(3–4):104-112.
• [23]Mohan S, Ahmad AS, Glushakov AV, Chambers C, Dore S: Putative role of prostaglandin receptor in intracerebral hemorrhage. Front Neurol 2012, 3:145.
• [24]Ahmad AS, Saleem S, Ahmad M, Doré S: Prostaglandin EP1 receptor contributes to excitotoxicity and focal ischemic brain damage. Toxicol Sci 2006, 89(1):265-270.
• [25]Candelario-Jalil E, Slawik H, Ridelis I, Waschbisch A, Akundi RS, Hull M, et al.: Regional distribution of the prostaglandin E2 receptor EP1 in the rat brain: accumulation in purkinje cells of the cerebellum. J Mol Neurosci 2005, 27(3):303-310.
• [26]Andreasson K: Prostaglandin signalling in cerebral ischaemia. Br J Pharmacol 2010, 160(4):844-846.
• [27]Sugimoto Y, Narumiya S, Ichikawa A: Distribution and function of prostanoid receptors: studies from knockout mice. Prog Lipid Res 2000, 39(4):289-314.
• [28]Saleem S, Li RC, Wei G, Doré S: Effects of EP1 receptor on cerebral blood flow in the middle cerebral artery occlusion model of stroke in mice. J Neurosci Res 2007, 85(11):2433-2440.
• [29]Katoh H, Watabe A, Sugimoto Y, Ichikawa A, Negishi M: Characterization of the signal transduction of prostaglandin E receptor EP1 subtype in cDNA-transfected Chinese hamster ovary cells. Biochim Biophys Acta 1995, 1244(1):41-48.
• [30]Shimamura M, Zhou P, Casolla B, Qian L, Capone C, Kurinami H, et al.: Prostaglandin E2 type 1 receptors contribute to neuronal apoptosis after transient forebrain ischemia. Journal Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab 2013, 33(8):1207-1214.
• [31]Fukumoto K, Takagi N, Yamamoto R, Moriyama Y, Takeo S, Tanonaka K: Prostanoid EP1 receptor antagonist reduces blood-brain barrier leakage after cerebral ischemia. Eur J Pharmacol 2010, 640(1–3):82-86.
• [32]Taniguchi H, Anacker C, Suarez-Mier GB, Wang Q, Andreasson K: Function of prostaglandin E2 EP receptors in the acute outcome of rodent hypoxic ischemic encephalopathy. Neurosci Lett 2011, 504(3):185-190.
• [33]Kawano T, Anrather J, Zhou P, Park L, Wang G, Frys KA, et al.: Prostaglandin E 2 EP1 receptors: downstream effectors of COX-2 neurotoxicity. Nat Med 2006, 12(2):225-229.
• [34]Kiriyama M, Ushikubi F, Kobayashi T, Hirata M, Sugimoto Y, Narumiya S: Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol 1997, 122(2):217-224.
• [35]Hase S, Yokota A, Nakagiri A, Takeuchi K: Prostaglandin E2 aggravates gastric mucosal injury induced by histamine in rats through EP1 receptors. Life Sci 2003, 74(5):629-641.
• [36]Leclerc JL, Lampert AS, Diller MA, Dore S: Genetic deletion of the prostaglandin E2 E prostanoid receptor subtype 3 improves anatomical and functional outcomes after intracerebral hemorrhage. Eur J Neurosci 2015, 41(10):1381-1391.
• [37]Taylor RA, Sansing LH: Microglial responses after ischemic stroke and intracerebral hemorrhage. Clin Develop Immunol 2013, 2013:746068.
• [38]Kelley-Hickie LP, Kinsella BT: EP1- and FP-mediated cross-desensitization of the alpha (alpha) and beta (beta) isoforms of the human thromboxane A2 receptor. Br J Pharmacol 2004, 142(1):203-221.
• [39]Zhang Y, Barres BA: Astrocyte heterogeneity: an underappreciated topic in neurobiology. Curr Opin Neurobiol 2010, 20(5):588-594.
• [40]Kang W, Hebert JM: Signaling pathways in reactive astrocytes, a genetic perspective. Mol Neurobiol 2011, 43(3):147-154.
• [41]Bush TG, Puvanachandra N, Horner CH, Polito A, Ostenfeld T, Svendsen CN, et al.: Leukocyte infiltration, neuronal degeneration, and neurite outgrowth after ablation of scar-forming, reactive astrocytes in adult transgenic mice. Neuron 1999, 23(2):297-308.
• [42]Faulkner JR, Herrmann JE, Woo MJ, Tansey KE, Doan NB, Sofroniew MV: Reactive astrocytes protect tissue and preserve function after spinal cord injury. J Neurosci Off J Soc Neurosci 2004, 24(9):2143-2155.
• [43]Muller WA: Migration of leukocytes across endothelial junctions: some concepts and controversies. Microcirculation 2001, 8(3):181-193.
• [44]Muller WA: Mechanisms of leukocyte transendothelial migration. Ann Rev Pathol 2011, 6:323-344.
• [45]Carman CV, Springer TA: Trans-cellular migration: cell-cell contacts get intimate. Curr Opin Cell Biol 2008, 20(5):533-540.
• [46]Muller WA: The role of PECAM-1 (CD31) in leukocyte emigration: studies in vitro and in vivo. J Leukoc Biol 1995, 57(4):523-528.
• [47]Winger RC, Koblinski JE, Kanda T, Ransohoff RM, Muller WA: Rapid remodeling of tight junctions during paracellular diapedesis in a human model of the blood-brain barrier. J Immunol 2014, 193(5):2427-2437.